Overview

NeuroXess is one of China’s leading implantable BCI companies, having completed the country’s first prospective invasive brain-computer interface human trial in 2025. The company is now building what it calls China’s first dedicated BCI production facility, signalling a shift from lab-bench prototyping to scale manufacturing.

Technology

NeuroXess develops polyimide mesh electrodes — a non-penetrating design that conforms to the brain’s surface without piercing cortical tissue. The implant is fully integrated with an internal battery, eliminating external power requirements. The company has demonstrated a data transmission rate of 5.2 bits per second and accumulated significant human implant experience.

Manufacturing

In March 2026 NeuroXess broke ground on a 14,300-square-metre production facility in Jiangxi province, designed to produce tens of thousands of BCI units. The facility represents a significant step toward mass manufacturing of implantable neural interfaces in China.

Competitive Position

NeuroXess is positioned as a direct global competitor to Neuralink and other Western BCI companies, leveraging government support, lower development costs, and a rapidly maturing regulatory environment to accelerate commercial timelines. Co-founder Phoenix Peng departed in 2025 to launch Gestala, an ultrasound-focused BCI startup.